Two diabetes drugs under review over acute kidney disease
The TGA is considering strengthening an existing safety warning about the risk of acute kidney injury for two diabetes drugs.
The review applies to SGLT2 inhibitors for type 2 diabetes that include dapagliflozin (Forxiga, Xigduo XR) and canagliflozin (Invokana).
It does not apply to a newer SGLT2 drug empagliflozin (Jardiance).
All three drugs were subject to a TGA advisory notice last year about the risk of diabetic ketoacidosis.
Related News: Ketoacidosis caution for diabetes drug